Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats.
Intrastriatal injection of the endogenous excitotoxin quinolinate in experimental animals causes a lesion which duplicates many features of Huntington's disease (HD). This lesion can be prevented by a related metabolite, kynurenate. Since kynurenate levels are reduced in the HD neostriatum, a deficiency in brain kynurenate may be the cause of neuron loss in HD. In order to investigate the relationship between excitotoxic neurodegeneration and kynurenate formation, effects of a unilateral quinolinate injection on several measures of kynurenate metabolism were studied in the rat striatum and substantia nigra. Within 2 hours, quinolinate caused an approximately 100% increase in striatal kynurenate levels in the absence of changes in its bioprecursor L-kynurenine or its biosynthetic enzymes kynurenine aminotransferases (KATs) I and II. This increase was more dramatic after 2 days (+735%) and was accompanied by an increase in L-kynurenine (+182%). No change or a slight decrease in enzyme activities were detected at this time-point. More chronic excitotoxic lesions produced a substantial increase in kynurenate levels (by approximately 2-, 4- and 4-fold, respectively, after 7 days, 1 and 5 months). Lesion-induced changes in KAT II activity essentially paralleled those seen with kynurenate, whereas KAT I remained slightly decreased at all timepoints. Nigral KAT II activity was increased ipsilaterally 2 days, 1 and 5 months after the striatal quinolinate injection. Kinetic analyses, performed in the striatum 5 months after the quinolinate injection, showed an almost 3-fold decrease in Km values for KAT II in the absence of v(max) changes. These findings indicate that 1) different mechanisms regulate kynurenate production at different stages after an intrastriatal quinolinate injection; 2) an increased substrate affinity to KAT II is responsible for the elevation of kynurenate in the chronically lesioned rat striatum; and 3) qualitative differences in kynurenate metabolism exist between the HD neostriatum and the excitotoxin-lesioned rat striatum, supporting the idea that (a decrease in) kynurenate tone may play a primary role in the pathophysiology of HD.
Ceresoli-Borroni
G
G
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, USA.
Guidetti
P
P
Schwarcz
R
R
D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D005968:Glutamate Decarboxylase / Q000378:metabolism; D007267:Injections; D007527:Isoenzymes / Q000378:metabolism; D007700:Kinetics; D007736:Kynurenic Acid / Q000378:metabolism*; D008190:Lyases; D008297:Male; D017378:Quinolinic Acid / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000201:enzymology / Q000378:metabolism; D013997:Time Factors; D000637:Transaminases / Q000378:metabolism
D007527:Isoenzymes; D000637:Transaminases; C427605:glutamine - phenylpyruvate transaminase; C021481:kynurenine-oxoglutarate transaminase; D008190:Lyases; D005968:Glutamate Decarboxylase; D017378:Quinolinic Acid; D007736:Kynurenic Acid